Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Both beta-blockers (BBs) and angiotensin converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) reduce mortality risk in patients with acute myocardial infarction (AMI) managed with revascularization, according to a recent Singapore study.
The combination of pitavastatin and fenofibrate appears to have superior effect on non-high-density lipoprotein cholesterol (non–HDL-C), as well as other lipids, compared with a statin alone in high-risk patients with mixed dyslipidemia, according to a study.
Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.
Nurses play a critical role during a respiratory pandemic, and this systematic review further stresses the need for governments, policy makers, and nursing groups to actively engage in supporting them, both during and following a pandemic or epidemic. The absence of such support system may result in substantial psychological issues among nurses, leading to burnout and loss from the nursing workforce.
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Patients with the coronavirus disease 2019 (COVID-19) have an altered faecal microbiome, characterized by enrichments in opportunistic pathogens, and depletions of beneficial commensals, according to a recent study.
Daily albumin infusion to achieve serum albumin levels of ≥30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.